Drug
Pelacarsen clinical trials
Also written TQJ230.
Includes 4 studies of Pelacarsen sodium.
- studies test it
- 15
- open now
- 1
- in phase 3
- 6
- first study started
- 2015
Keep track of what changes. Save the pelacarsen studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
15 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 2
- Phase 3
- 6
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 1
Novartis Pharmaceuticals (8) · Akcea Therapeutics (4) · Ionis Pharmaceuticals, Inc. (2) · University Medical Centre Ljubljana (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses pelacarsen is read from its arms, and is right about nine times in ten.
Testing it · 15
- A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve StenosisRecruitingPhase 2Novartis PharmaceuticalsNCT05646381Written as Pelacarsen (TQJ230) 80mg
- An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05900141Written as Pelacarsen
- Pelacarsen Roll-over Extension ProgramActive, not recruitingPhase 3Novartis PharmaceuticalsNCT06875973Written as Pelacarsen (TQJ230)
- Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVDActive, not recruitingPhase 3Novartis PharmaceuticalsNCT06813911Written as Pelacarsen
- An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT07517263Written as Pelacarsen (TQJ230)
- Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARLWithdrawnPhase 3Novartis PharmaceuticalsNCT07625306Written as Pelacarsen
- A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in GermanyCompletedPhase 3Novartis PharmaceuticalsNCT05305664Written as Pelacarsen (TQJ230) 80 mg s.c.
- Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy ParticipantsCompletedPhase 1Novartis PharmaceuticalsNCT05026996Written as Pelacarsen
- A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese ParticipantsCompletedPhase 1Ionis Pharmaceuticals, Inc.NCT05337878Written as Pelacarsen
- Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)WithdrawnNot applicableUniversity Medical Centre LjubljanaNCT04993664Written as Pelacarsen (TQJ230)
- Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular DiseaseCompletedPhase 2Akcea TherapeuticsNCT03070782Written as ISIS 681257
- Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy PatientsCompletedPhase 1Akcea TherapeuticsNCT03506854Written as ISIS 681257
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)CompletedPhase 1Ionis Pharmaceuticals, Inc.NCT02414594Written as IONIS-APO(a)-LRx
- Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on WarfarinCompletedPhase 1Akcea TherapeuticsNCT03426033Written as ISIS 681257
- Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on ClopidogrelCompletedPhase 1Akcea TherapeuticsNCT03392051Written as ISIS 681257
Codes
What other systems call pelacarsen · ClinicalTrials.gg INT002089
- MeSH (NLM) C000730804pelacarsenOne source ClinicalTrials.gov
- UNII (FDA) LSO9H7UZ90PELACARSENOne source FDA
- NCI Thesaurus C174676PelacarsenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000730804 | pelacarsen | One source ClinicalTrials.gov |
| UNII (FDA) | LSO9H7UZ90 | PELACARSEN | One source FDA |
| NCI Thesaurus | C174676 | Pelacarsen | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.